Patent Application
20220387575
The present disclosure belongs to the fields of genetic engineering and new vaccine development, and relates to a Mycobacterium bovis Bacillus Calmette-Guerin (BCG) strain and in particular to a construction method of a recombinant drug-resistant BCG strain and a pharmaceutical composition for treating tuberculosis (TB).
The Sequence Listing XML file submitted via the USPTO Patent Center, with a file name of “Sequence listing.XML”, a creation date of Aug. 12, 2022, and a size of 41 KB, is part of the specification and is incorporated in its entirety by reference herein.
TB, also known as phthisis and “white plague”, is an ancient and protracted infectious disease, and is one of the serious diseases that endanger the human health for a long time. TB is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) infection, which is a pathogen causing TB. Mtb can invade various organs of the human body, and invades the lung most often. About one third of the global population is infected with Mtb, and about 1.5 million people die from TB each year, with an average of more than 4,000 deaths per day.
In recent years, due to the dual infection of human immunodeficiency virus (HIV) and Mtb and the prevalence of drug-resistant Mtb, the incidence and mortality of TB have risen sharply, making the situation more severe. The United Nations has listed TB as one of the three major diseases to be controlled in the 21st century. TB can be cured, but requires a relatively long treatment cycle. TB caused by drug-susceptible Mtb requires a standard treatment course of 6 months, during which the 4 first-line drugs of INH, RIF, PZA, and EMB are administered during the first two months, and then INH and RIF are administered for another two months. The emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) TB strains makes the prevention and treatment of TB face greater challenges. The MDR strain is resistant to the two most effective drugs INH and RIF, the XDR strain is resistant to INH, RIF, at least one quinolone, and one second-line injectable drug, and the TDR strain can be resistant to more drugs. To treat patients infected with the MDR strain, a treatment course needs to be extended to 9 to 24 months and a number of drugs administered also needs to be increased to 5 to 8, but a cure rate is reduced to less than 50%. The treatment of patients infected with the XDR and TDR strains requires an extended treatment cycle and has a reduced cure rate. After TB is treated for about two months, the number of bacteria in the body is reduced to be about 10,000 to 100,000; if the drug administration is stopped, the number of bacteria will rebound immediately; and after the rebound, a treatment with the same drug is still effective, in which case Mtb does not become resistant to the drug due to genomic mutations and are merely in a state similar to dormant infection. Such a state is called a persistence state, and such bacteria are called persistence bacteria.
BCG (Mycobacterium bovis (M. bovis) BCG) is the only vaccine that can prevent TB. Although having been widely used in the world for over 100 years, BCG exhibits an unstable protective effect (0% to 80%), is almost ineffective for adults, and cannot exert a therapeutic effect for infected patients. However, an immunization effect of BCG in the body continues to weaken with age, and even if BCG is vaccinated once again in the adulthood, the effect of preventing TB cannot be achieved. BCG is susceptible to anti-TB drugs and thus is easily cleared by anti-TB drugs like Mtb, which is the most obvious defect. Therefore, when used as a therapeutic TB vaccine (for TB patients), BCG is killed. So it is difficult for BCG to play an immunoprotective role and is difficult to compete with Mtb from the perspective of microecology. In addition, the common recombinant BCG is mainly obtained by introducing an abundantly-expressed antigen protein which ignores an antigen expressed when Mtb enters a quiescent stage (a metabolically-inactive state). A therapeutic TB vaccine can be used in combination with an existing drug to shorten a TB treatment course. There are currently the following two main therapeutic TB vaccines: RUTI vaccine, which is mainly obtained by detoxifying inactivated Mtb fragments and then constructing resulting fragments in a liposome and can be used to treat latent TB infection; and SRL-172 vaccine, which is composed of heat-inactivated Mycobacterium vaccae (M. vaccae) or purified proteins from M. vaccae and can be used for adjuvant treatment of Mtb patients. These two therapeutic vaccines have a common disadvantage that they cannot induce sustained immunity and microecological protection after treatment.
There is an urgent need for a therapeutic vaccine with a novel action mechanism that can shorten a treatment cycle and is effective for TB caused especially by drug-resistant Mtb. A drug-resistant recombinant BCG vaccine prepared based on the combination of microecological competition theory, immunotherapy, and chemotherapy is very promising for the treatment of patients infected with drug-resistant Mtb.
In view of the above problems, the present disclosure is intended to provide a therapeutic vaccine that can shorten a treatment cycle and is effective for TB caused by drug-resistant Mtb, and a pharmaceutical composition for treating TB.
To achieve the above objective, the present disclosure adopts the following technical solutions: A drug-resistant BCG strain is provided, where the drug-resistant BCG strain is a mutant strain of M. bovis BCG, and the drug-resistant BCG strain includes at least one selected from the group consisting of the following gene mutations: 660G>A (the numbering starts from the first nucleotide of a start codon that is numbered 1, and “G>A” means that a nucleotide G at this position is mutated into a nucleotide A; and the following gene mutations are numbered and expressed in the same way) of embB gene, 417A>G or 216C>T of embC gene, 145G>A or 228T>C or 447A>C or 483C>T of Rv3806c gene, 128G>A of rpsL gene, 192delG of rrs gene, 448C>A of eis gene, 262G>A or 263G>A of gyrA gene, and 63T>C of ethA gene.
As a preferred embodiment of the present disclosure, the drug-resistant BCG strain may be a mutant strain of M. bovis BCG, and the drug-resistant BCG strain may include the following gene mutations: 660G>A of embB gene, 417A>G or 216C>T of embC gene, 145G>A or 228T>C or 447A>C or 483C>T of Rv3806c gene, 128G>A of rpsL gene, 192delG of rrs gene (“del” represents “deletion”), 448C>A of eis gene, 262G>A or 263G>A of gyrA gene, and 63T>C of ethA gene.
Preferably, the drug-resistant BCG strain may be named as drug-resistant BCG, and was deposited in the Guangdong Microbial Culture Collection Center (GDMCC) located at Guangdong Institute of Microbiology, No. 100 Xianlie Middle Road Guangzhou, China (on Feb. 28, 2020), with an accession number of GDMCC 60969.
The present disclosure also provides a method for preparing a TB vaccine with the drug-resistant BCG strain.
Further, the present disclosure also provides a construction method of a recombinant drug-resistant BCG strain, including transforming a plasmid carrying sequences of Mtb-identifying protein-associated genes into the drug-resistant BCG strain described above.
As a preferred embodiment of the present disclosure, the Mtb-identifying protein-associated genes may be genes Ag85b and Rv2628.
The genes Ag85b and Rv2628 can express related antigens in an active stage and a latent stage respectively, and can provide immune protection in different growth phases of Mtb, thereby improving a protective effect of the vaccine.
The present disclosure also provides a recombinant drug-resistant BCG strain obtained according to the method described above.
Further, the recombinant drug-resistant BCG strain can be used to prepare a pharmaceutical composition for treating TB, and the pharmaceutical composition includes the recombinant drug-resistant BCG strain.
The recombinant drug-resistant BCG strain can compete with Mtb for growth, thereby accelerating the death of Mtb. When used in combination with a drug for treating TB, the recombinant drug-resistant BCG strain can further enhance a therapeutic effect for Mtb (drug-resistant Mtb), and can also avoid re-infection of a patient, which has promising medical prospects.
As a preferred embodiment of the present disclosure, the pharmaceutical composition may further include at least one selected from the group consisting of ethambutol (EMB), levofloxacin (LFX), prothionamide (PRO), and amikacin (AMK).
As a preferred embodiment of the present disclosure, the pharmaceutical composition may further include EMB, LFX, PRO, and AMK.
The present disclosure provides a drug-resistant BCG strain that can be used in combination with a chemical drug. As a therapeutic vaccine, the drug-resistant BCG strain will not be affected by a drug for treating TB, and thus can survive in the human body and compete with the disease-causing Mtb for growth, thereby accelerating the death of Mtb. The drug-resistant BCG strain can be further modified to obtain a recombinant drug-resistant BCG strain, and the recombinant drug-resistant BCG strain can be used to treat patients infected with Mtb and especially MDR Mtb, which can produce antigens against Mtb to cause a strong immune response. In addition, after treatment, the recombinant drug-resistant BCG strain can continue to survive in the body for a specified period of time, which helps to protect a patient and reduce a risk of re-infection.
To better explain the objectives, technical solutions, and advantages of the present disclosure, the present disclosure will be further explained below with reference to accompanying drawings and specific examples.
I. Preparation of 7H9 and 7H11 Culture Media
1. 7H9 liquid culture medium: 4.7 g of 7H9 powder, 2 mL of glycerol, and 900 mL of ddH2O were mixed, sterilized at a high temperature and a high pressure, and then cooled, and 100 mL of OADC was added; and
2. 7H11 solid culture medium: 19 g of 7H11 powder, 5 mL of glycerol, and 900 mL of ddH2O were mixed, sterilized at a high temperature and a high pressure, and then cooled, and 100 mL of OADC was added.
II. Screening of Spontaneously Drug-Resistant BCG
1. With a minimal inhibitory concentration (MIC) of M. bovis BCG (hereinafter referred to as wild-type (WT) BCG, which was provided by Johns Hopkins University School of Medicine) for streptomycin (STR) being 0.25 μg/mL, a streptomycin (STR)-containing 7H11 plate (with a final concentration of 0.25*MIC-8*MIC) and a 7H11 blank plate were prepared. M. bovis BCG at a logarithmic growth phase was taken and diluted to an appropriate concentration, then 500 μL of a resulting bacterial suspension was pipetted and evenly spread on the plates. The plates were incubated in a constant-temperature incubator for four weeks. Then the colony count was conducted, and MIC was calculated. This method was used to detect the MIC of M. bovis BCG for STR, LFX, EMB, PRO, para-aminosalicylic acid (PAS), and AMK.
2. According to the obtained MIC value for STR, 7H11 plates with different concentrations of STR (0.5*MIC-128*MIC) and a blank 7H11 plate were prepared. BCG at a logarithmic growth phase (OD600=0.6 to 0.8) was taken, and 500 μL of a bacterial solution was evenly spread on each plate and then cultivated in a constant-temperature incubator for 4 weeks; single colonies were picked, inoculated into a 50 mL centrifuge tube with the 7H9 culture medium, and cultivated on a shaker. After the single colonies grew to a logarithmic phase, a bacterial solution was taken for polymerase chain reaction (PCR) and sequencing to confirm an STR-resistant BCG strain obtained.
3. The STR-resistant BCG strain obtained was cultivated on 7H11 plates each with a first-line or second-line anti-TB drug (an order of screening drugs: LFX, EMB, PRO, PAS, and AMK) according to the method in 2, then single colonies were picked and cultivated in a 50 mL centrifuge tube with the 7H9 culture medium, and identification was conducted to finally obtain a BCG strain resistant to STR, LFX, EMB, PRO, PAS, and AMK (referred to as drug-resistant BCG).
Target genes and primer sequences of the above drugs were shown in Table 1.
4. The spontaneously drug-resistant BCG finally obtained after the screening was identified and inoculated into a 50 mL centrifuge tube with the 7H9 culture medium and cultivated on a shaker; after growing to a logarithmic phase, the BCG was diluted to an appropriate concentration, and 500 μL of a resulting bacterial solution was pipetted and spread on each of 7H11 plates with a single screening drug mentioned above (drug concentration: 0.5*MIC-128*MIC) and a blank 7H11 plate, and cultivated in a constant-temperature incubator for 4 weeks; and the colony count was conducted, and then an MIC of the drug-resistant BCG strain for each screening drug was calculated. The MICs and drug resistance mechanisms of the drug-resistant BCG obtained after the sequencing to the screening drugs were shown in Table 2.
The drug-resistant BCG strain was named as drug-resistant BCG, and was deposited in the Guangdong Microbial Culture Collection Center (GDMCC) located at Guangdong Institute of Microbiology, No. 100 Xianlie Middle Road Guangzhou, China on Feb. 28, 2020, with an accession number of GDMCC 60969.
I. Construction of a Recombinant Plasmid Carrying Ag85b and Rv2628 Gene Fragments
1. PCR Product Recovery and Digestion
A construction process of the plasmid was shown in
The recovered and identified Rv2628 fragment and the starting plasmid p60LuxN (the plasmid was constructed by the laboratory of the present disclosure, a map of the plasmid was shown in
2. Ligation and Transformation
After the digestion products were recovered, a volume ratio of gene fragments to vector fragments in an enzyme ligation system was further determined to be 3:1 through agarose gel electrophoresis comparison. The enzyme ligation system was prepared according to Table 4, and ligation was conducted overnight at 16° C.
A ligation product was added to 50 μL of an Escherichia coli (E. coli) DH5α competent cell solution prepared in the laboratory, and a resulting mixture was allowed to stand on ice for 30 min and then transferred to a water bath at 42° C.; then the mixture was subjected to heat shock for 90 s, and then placed on ice for 2 min; 1 mL of an LB liquid culture medium was added, the competent cells were cultivated on a shaker at 37° C. and 180 rpm/min for 1 h, and a resulting bacterial solution was centrifuged; and a resulting supernatant was removed, and resulting bacterial cells were resuspended with 800 μL of an LB liquid culture medium, spread on an LB solid culture medium (with 50 μg/mL hygromycin), and cultivated in a 37° C. incubator for 16 h.
3. Identification of the Recombinant Plasmid
The above-mentioned primers for amplifying the Rv2628 gene fragment were used to conduct PCR identification on single colonies picked from the LB plate, and single colonies identified as positive by PCR were inoculated into 5 mL of an LB culture medium and cultivated on a 37° C. shaker for 12 h to 16 h. A resulting bacterial solution was collected and subjected to plasmid extraction. An extracted plasmid was identified by double enzyme digestion with Nde I and Pst I, and if an identification result was positive, the plasmid was sent to a company for sequencing. A plasmid with a correct sequence was named as p60Rv2628.
4. The plasmid p60Rv2628 obtained and the Ag85b gene fragment amplified by PCR were subjected to digestion with BamH I and Hind III, ligation, transformation, and identification according to the above-mentioned method to obtain a plasmid carrying both the Ag85b gene fragment and the Rv2628 gene fragment, which was named as pEBCG.
5. The plasmid pEBCG obtained (as shown in
II. Construction of a Recombinant Drug-Resistant BCG Strain
The plasmids p60LuxNC (control) and pIBCG were each electroporated into competent BCG (prepared from the drug-resistant BCG prepared in Example 1) with an electroporator at 2.5 Kv. An electroporation cuvette was rinsed with the 7H9 culture medium, a resulting bacterial solution was transferred to a 50 mL centrifuge tube, an appropriate amount of the 7H9 culture medium was added, the bacterial solution was cultivated for 20 h; then 500 μL of a resulting bacterial solution was taken and spread on a hygromycin (50 μg/mL)-containing 7H11 plate, and the plate was incubated in a constant-temperature incubator at 37° C. for 4 weeks. Colonies were picked and inoculated in a 7H9 culture medium (with 10 μg/mL hygromycin) and cultivated for 4 weeks. A resulting bacterial solution was serially diluted to 1,000 times, and diluted bacterial solutions were spread on hygromycin (50 μg/mL)-containing and blank 7H11 plates and cultivated for 5 weeks. Single colonies on the hygromycin-containing plate were picked, subjected to expanded cultivation, and DNA extraction. A primer pair Mark-F (5′-CGATGTGGTCGGATAGGCA-3′, SEQ ID NO: 45) and Mark-R (5′-ACTCACCTGCGGTTTATCTGC-3′, SEQ ID NO: 46) was used for amplification and identification to obtain a 0.6 kb fragment (that is, a fragment including the Ag85B gene and the Rv2628 gene), indicating that the recombinant drug-resistant BCG strain was successfully constructed.
The recombinant drug-resistant BCG obtained was diluted to an appropriate concentration, cultivated in a hygromycin-containing 7H9 culture medium, and continuously subcultured five times. Bacterial solutions of passages 4 and 5 each were serially diluted, spread on a hygromycin-containing 7H11 plate, and cultivated in an incubator for four weeks. Single colonies were picked, subjected to expanded cultivation, and DNA extraction. A primer pair Mark-F (5′-CGATGTGGTCGGATAGGCA-3′, SEQ ID NO: 45) and Mark-R (5′-ACTCACCTGCGGTTTATCTGC-3′, SEQ ID NO: 46) was used for amplification and identification to obtain a 0.6 kb fragment, that is, a fragment including the Ag85B gene and the Rv2628 gene.
Colonies obtained after 5 consecutive times of subculture were randomly picked, and colony PCR was conducted using the above primer pair (Mark-F and Mark-R). Results were shown in
The recombinant drug-resistant BCG strain constructed was inoculated into a 50 mL centrifuge tube with the 7H9 culture medium, and cultivated on a shaker; after the strain grew to a logarithmic phase, a resulting bacterial solution was appropriately diluted, and 500 μL of a diluted bacterial solution was spread on a 7H11 plate with EMB, STR, AMK, LFX, moxifloxacin, PAS, PRO, clofazimine (CLA), isoniazid, rifampicin, Pretomanid (PA-824), bedaquiline (TMC207), or linezolid (LZD) and a blank 7H11 plate and cultivated in a constant-temperature incubator for 4 weeks; and the colony count was conducted, and then an MIC of the recombinant drug-resistant BCG strain for each screening drug was calculated (as shown in
M. bovis BCG
SCID mice each with a body weight of 14 g to 17 g were selected and adaptively raised in the laboratory for a few days, and then a WT BCG bacterial solution and a recombinant drug-resistant BCG bacterial solution with an OD600 of 0.8 to 1.0 were taken and then each injected into 30 SCID mice through the tail vein at a dose of 200 μL/mouse.
According to the type of injected bacteria, mice were randomly divided in cages, with 5 mice in each cage. After being divided into cages, the mice were raised according to the feeding standards of SCID mice. Survival statuses of the mice were observed and recorded every day and the mice in each group were weighed every week. Results were shown in
On day 2 after the injection, 3 mice were taken from each group and weighed, the spleen and lung were collected, and the spleen was weighed; and the lung tissue was thoroughly ground, diluted to an appropriate concentration, spread on a 7H11 plate, and cultivated in a constant-temperature incubator for 4 weeks, and the colony count was conducted to calculate a bacterial load.
At week 2 and 4 after the injection, 5 mice were taken from each group and weighed, the spleen and lung were collected, and the spleen was weighed (results were shown in
It can be seen from
The autoluminescent Mtb H37Rv (ALRV) with an OD600 of 0.8 to 1.0 and the recombinant drug-resistant BCG bacteria (rdrBCG) were each serially diluted (with a dilution gradient in Table 6), and a stock solution and diluted solutions of ALRV were each mixed with each of a stock solution and diluted solutions of rdrBCG in a 50 mL centrifuge tube according to a specified volume ratio. A mixed bacterial solution was cultivated in a constant-temperature incubator, and a relative luminescence value (RLU) was detected regularly. Results were shown in
It can be seen from
1. Preparation and Validation of Rifampicin-Resistant Mtb H37Rv
An Mtb H37Rv bacterial solution with OD600 of 0.8 to 1.0 was taken, and concentrated 10 times and 20 times. A stock solution was sequentially diluted to 10−4 and 10−6, and then 500 μL of each of the stock solution, the 10−4 diluted solution, and the 10−6 diluted solution was taken and evenly spread on a 7H11 blank plate to calculate the number of Mtb in a bacterial solution. 500 μL of a concentrated solution was taken and evenly spread on 7H11 plates with different concentrations of rifampicin (4 μg/mL and 10 μ/mL), and then cultivated in a constant-temperature incubator; and after there were colonies, single colonies were picked and cultivated in a 50 mL centrifuge tube, and a mutation of the rifampicin resistance-related gene rpoB was detected by sequencing. A mutation (TCG-TTG) was found at position 531 (with the first nucleotide of a start codon as position 1) after sequence alignment, which was consistent with that reported in literatures.
2. Infection, Treatment, and Immunization of Mice
BALB/C mice (80 mice) each with a weight of 14 g to 17 g were adaptively raised for a few days in the P3 laboratory, then subjected to aerosol infection for 45 min through Glas-Col using rifampicin-resistant Mtb H37Rv with OD600 of 0.8 to 1.0, and then randomly divided into cages, with 5 mice in each cage, including 15 mice for the untreated group, 25 mice for the treated group (Tt), 20 mice for the WT BCG immunotherapy group (Tt+wt), and 20 mice for the recombinant drug-resistant BCG immunotherapy group (Tt+rdr).
On day 1 and day 28 after the infection, 5 mice were taken from the untreated group and sacrificed, the lung was collected, thoroughly ground, diluted to an appropriate concentration, spread on a 7H11 plate, and cultivated in a constant-temperature incubator for 4 weeks, and the colony count was conducted to calculate a bacterial load. At other detection time points, 5 mice were sacrificed according to the experimental protocol in Table 7, and a bacterial load was detected by the same method.
The treatment was started on day 28 after the infection, where the drugs were administered once a day, 5 days a week. Early-stage treatment (two months) regimen: EMB (150 mg/kg, intragastrically), LFX (300 mg/kg, intragastrically), PRO (25 mg/kg, intragastrically), and AMK (100 mg/kg, subcutaneously); and late-stage treatment (three months) regimen: EMB (150 mg/kg, intragastrically), LFX (300 mg/kg, intragastrically), and PRO (25 mg/kg, intragastrically). After two months of treatment, aerosol infection (as) and subcutaneous injection (sc) were used for immunization. rdrBCG at a logarithmic growth phase was centrifuged, a resulting supernatant was discarded, PBS was added to resuspend, and an OD600 value was adjusted to 0.5 for immunization. Aerosol infection immunization: Glas-Col was used to conduct aerosol infection for 45 min to achieve immunization; and subcutaneous injection immunization: 200 μL of a bacterial solution was subcutaneously injected. The subsequent immunization schedule and bacterial load detection schedule were shown in Table 7.
*The day after infection, five mice were sacrificed.
The bacterial load detection results were shown in
Finally, it should be noted that the above examples are provided merely to describe the technical solutions of the present disclosure, rather than to limit the protection scope of the present disclosure. Although the present disclosure is described in detail with reference to preferred examples, a person of ordinary skill in the art should understand that modifications or equivalent replacements may be made to the technical solutions of the present disclosure without departing from the spirit and scope of the technical solutions of the present disclosure.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202010134454.3 | Feb 2020 | CN | national |
The present application is a continuation-in-part application of PCT application No. PCT/CN2021/076989 filed on Feb. 20, 2021, which claims the benefit of Chinese Patent Application No. 202010134454.3 filed on Feb. 28, 2020, each of which is incorporated by reference herein in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CN2021/076989 | Feb 2021 | US |
| Child | 17886480 | US |
